Removal of serine proteases by treatment with finely divided silicon dioxide

US8772462B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH

Inventors

• Wolfgang Teschner · Wien, AT
• Hans-Peter Schwarz · Wien, AT
• Ruth Madlener · Wien, AT
• Sonja Svatos · Ybbs an der Donau, AT
• Azra Pljevljakovic · Wien, AT
• Alfred Weber · Wien, AT

Key dates

• Filing date: May 26, 2011
• Grant date: Jul 8, 2014
• Expiry date: May 30, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K1/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease andor serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.